Cabenuva (cabotegravir long acting/rilpivirine long acting) News

12 3 4 5 6 »

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Long-Acting Injectable ART in Practice: A Mixed Methods Implementation Study Assessing the Feasibility of Using LAI ART in High Risk Populations and At Alternative Low Barrier Care Sites. (Pubmed Central) - Apr 24, 2024
To ensure equitable access to new treatment modalities, we examined the feasibility and acceptability of administering Cabotegravir Rilpivirine Long Acting (CAB/RPV LA) to individuals who experience challenging social determinants of health (SDoH) and struggle with adherence to traditional oral ART...While LAI has major potential benefits for high-risk patients, these benefits must be balanced with the complexities of implementation. Despite challenges that impacted study outcomes, improving treatment outcomes for PLWH requires addressing SDoH and substance use.

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal, Adherence: Improving Adherence to the Target Window for Cabotegravir + Rilpivirine Long-Acting Injections Through the CHORUS (Pubmed Central) - Apr 17, 2024
P=N/A
Despite challenges that impacted study outcomes, improving treatment outcomes for PLWH requires addressing SDoH and substance use. While access to CHORUS

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Identifying Implementation Determinants and Strategies for Long-Acting Injectable Cabotegravir-Rilpivirine in People with HIV Who Are Virally Unsuppressed. (Pubmed Central) - Mar 27, 2024
Multi-level strategies to support LA-CAB/RPV implementation for PWH without VS are required, which may necessitate additional resources in some settings to implement safely and effectively. Advocacy to eliminate outer-context barriers, including prior authorizations and specialty pharmacy restrictions, is needed.

|||||||||| Juluca (dolutegravir/rilpivirine) / ViiV Healthcare, J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi, Vemlidy (tenofovir alafenamide) / Gilead
Hepatitis B Reactivation in PLWH With Anti-Core Antibody After Switch to an Anti-HBV Sparing Regimen (Poster hall) - Mar 16, 2024 - Abstract #CROI2024CROI_875;
We decided to investigate HBV reactivation in antiHBc-PLWH (with isolated anti-HBc or with anti-HBc and anti-HBsAg) after the switch from ART including drugs active on both viruses (tenofovir disoproxil fumarate, TDF and tenofovir alafenamide, TAF) to an antiHBV sparing regimen (antiHBVsr) because in PLWH the loss of HBsAg with or without anti-HBsAg seroconversion is probably consequent to ART treatment including drugs active on both viruses (HIV/HBV) rather than past HBV infection. Additionally, HBV reactivation has been described in immunocompromised anti-HBsAg positive people.HBV reactivation in antiHBc-PLWH was assessed by an alteration of alanine aminotransferase (ALT) above the upper limit of the normal range after the switch to antiHBVsr dolutegravir/rilpivirine (DOL/RPV) or long acting therapy cabotegravir/rilpivirine (CAB/RPVLA)...The HBV reactivation is unlikely in antiHBc-PLWH with anti-HBsAg positivity after switch to anti-HBVsr, while close monitoring of ALT and possibly HBV-DNA in PLWH with antiHBc alone, after switch to anti-HBVsr is necessary.

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Method for Analyzing Cabotegravir and Rilpivirine in Hair May Help Identify Risk Factors for Failure (Poster hall) - Mar 16, 2024 - Abstract #CROI2024CROI_634;
The UCSF HIV Clinic (Ward 86) has ~250 patients on long-acting CAB/RPV with demographics typically assessed in population PK models (age, sex, BMI, etc.) available in the medical record. A research study to analyze CAB and RPV levels in hair and plasma, construct population PK models, and define risk factors for low LA CAB/RPV exposure, portending virologic failure, will be launched at Ward 86 using the hair method described here.

|||||||||| Apretude (cabotegravir extended-release injectable suspension) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Injectable Cabotegravir/Rilpivirine Reach and Effectiveness in a South Side Chicago HIV Clinic (Poster hall) - Mar 16, 2024 - Abstract #CROI2024CROI_542;
However, challenges exist in starting PWH on LAI CAB/RPV, especially among those without VS. More work is needed to support providers, patients, and clinic systems to deliver LAI-CAB/RPV to this group.

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Implementing Long-Acting ART in a Community Health Center: Insights and Early Outcomes (Poster hall) - Mar 16, 2024 - Abstract #CROI2024CROI_541;
These patients have maintained viral suppression at a high rate. We also provide further evidence suggesting efficacy of CAB-RPV LAI in non-suppressed PLWH who struggle with adherence to oral ART.

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Access to Long-Acting Injectable ART Through State AIDS Drug Assistance Programs (Poster hall) - Mar 16, 2024 - Abstract #CROI2024CROI_533;
States should consider expanding access to Cabenuva, including working to reduce supply and payment chain barriers, to promote equitable access to LAI ART. Future work should examine access to Cabenuva using patient-level data.

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Predictors of Injection Visit Adherence in Those Receiving Injectable Cabotegravir/Rilpivirine (Poster hall) - Mar 5, 2024 - Abstract #CROI2024CROI_494;
Background: Long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) provides a novel treatment option for people with HIV (PWH)... Evaluating attendance to office visits prior to switching to LAI CAB/RPV may help identify those more likely to miss injection visits, however it was not associated with late injections or having a detectable viral load or virologic failure.

|||||||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
HIV-1 RNA Blips and Low-Level Viral Replication: SOLAR (CAB+RPV LA vs BIC/FTC/TAF) (Poster hall) - Mar 5, 2024 - Abstract #CROI2024CROI_491;
P3
The proportions of study participants with HIV-1 RNA viral blips, TND, and HIV-1 RNA <40 c/mL were similar between CAB+RPV LA and BIC/FTC/TAF through Month 12. HIV-1 viral blips with CAB+RPV LA did not appear to be associated with CVF, consistent with prior CAB+RPV LA Phase 3 clinical study data.

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Real-World Virologic Outcomes of Cabotegravir/Rilpivirine in Patients With Elevated Body Mass Index (Poster hall) - Mar 5, 2024 - Abstract #CROI2024CROI_490;
HIV-1 viral blips with CAB+RPV LA did not appear to be associated with CVF, consistent with prior CAB+RPV LA Phase 3 clinical study data. Background: Injectable cabotegravir (CAB) and rilpivirine (RPV) is the first complete long-acting antiretroviral (ARV) regimen approved in persons with HIV with sustained virologic suppression (HIV RNA 50 copies/mL and VF were similar between groups regardless of BMI category.

|||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Sunlenca (lenacapavir) / Gilead
Case Series Examining the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial (Poster hall) - Mar 5, 2024 - Abstract #CROI2024CROI_489;
Background: Injectable cabotegravir (CAB) and rilpivirine (RPV) is the first complete long-acting antiretroviral (ARV) regimen approved in persons with HIV with sustained virologic suppression (HIV RNA 50 copies/mL and VF were similar between groups regardless of BMI category. The currently-approved LA-ART combination

|||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Randomized Trial of Cabotegravir and Rilpivirine Long-Acting in Africa (CARES): Week 48 Results () - Mar 5, 2024 - Abstract #CROI2024CROI_222;
CVF and acquired resistance was rare. LA was effective and safe and may be considered for use in treatment programs in sub-Saharan Africa.

|||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Edurant (rilpivirine) / J&J
Journal: Intradermal delivery of the antiretroviral drugs cabotegravir and rilpivirine by dissolving microarray patches: Investigation of lymphatic uptake. (Pubmed Central) - Mar 4, 2024
However, CAB MAPs delivered 7726?ng/g (T 7?days) to the external lumbar lymph nodes, which was statistically equivalent to IM delivery (C 8282?ng/g - T 7?days). This work provides strong evidence that MAPs were able to enhance the delivery of CAB and RPV to the lymphatic system compared to the IM delivery route.

|||||||||| Apretude (cabotegravir extended-release injectable suspension) / ViiV Healthcare, Sunlenca (lenacapavir) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Review, Journal: Polymer Delivery Systems for Long-Acting Antiretroviral Drugs. (Pubmed Central) - Feb 24, 2024
We posit that the physicochemical properties of the formulation chemical design can optimize drug release profiles. We posit that the strategic design of LA DDS polymers will further improve controlled drug release to simplify dosing schedules and improve regimen adherence.

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
PK/PD data, Journal: Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy. (Pubmed Central) - Feb 10, 2024
Model predictions suggest that monthly long-acting cabotegravir could maintain antiviral efficacy throughout pregnancy, but that bimonthly administration may require careful clinical evaluation. Both monthly and bimonthly long-acting rilpivirine may not adequately maintain antiviral efficacy in pregnancy.

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: who are they? (Pubmed Central) - Feb 1, 2024
Injectable cabotegravir and rilpivirine long-acting therapy is a revolutionary new antiretroviral treatment (ART) option for HIV infection in virologically suppressed adults on a stable ART. The aim of this study from SCOLTA multicenter observational prospective database is to describe the first people living with HIV (PWH) who started this regimen in Italy, assessing adherence to eligibility criteria, describing clinical-epidemiological characteristics compared to registration trials-population and describe early treatment-discontinuations.

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Early adopters of long-acting injectable cabotegravir/rilpivirine: what lessons can we learn? (Pubmed Central) - Feb 1, 2024
The aim of this study from SCOLTA multicenter observational prospective database is to describe the first people living with HIV (PWH) who started this regimen in Italy, assessing adherence to eligibility criteria, describing clinical-epidemiological characteristics compared to registration trials-population and describe early treatment-discontinuations. No abstract available

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Virological failure after switch to long-acting cabotegravir and rilpivirine injectable therapy: an in-depth analysis. (Pubmed Central) - Jan 11, 2024
This is the first in-depth multiple case analysis of VF on LA CAB/RPV therapy in a real-world setting. Our observations stress the need to be aware for (evolving) risk factors and the yield of a comprehensive clinical, virological and pharmacokinetic approach in case of failure.

||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Enrollment open:  Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age (clinicaltrials.gov) -  Dec 28, 2023
P1/2, N=90, Recruiting,  Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Our observations stress the need to be aware for (evolving) risk factors and the yield of a comprehensive clinical, virological and pharmacokinetic approach in case of failure. Not yet recruiting --> Recruiting

|||||||||| Rekambys (rilpivirine LA) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
P3 data, PK/PD data, Journal: Efficacy, safety, and pharmacokinetics by BMI category in Phase 3/3b cabotegravir?+?rilpivirine long-acting trials. (Pubmed Central) - Dec 22, 2023
Not yet recruiting --> Recruiting CAB?+?RPV LA was efficacious and well tolerated, regardless of baseline BMI category.Main point summary: CAB?+?RPV LA is effective in the maintenance of HIV-1 virologic suppression in adults regardless of BMI category, with longer-length needles (?2 inches) recommend for those with BMI ?30?kg/m2 to accommodate individual body habitus and ensure appropriate administration.

||||||||||  Vocabria (cabotegravir oral) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Trial completion, Patient reported outcomes:  Study to Assess the Effects of Cabotegravir (CAB) and Rilpivirine (RPV) Long-Acting (LA) Injections Following Sub-cutaneous (SC) Administration Compared With Intramuscular (IM) Administration in Adult Participants Living With Human Immunodeficiency Virus (HIV-1) Infection in the FLAIR Study (clinicaltrials.gov) -  Dec 21, 2023
P3, N=93, Completed,  Sponsor: ViiV Healthcare
CAB?+?RPV LA was efficacious and well tolerated, regardless of baseline BMI category.Main point summary: CAB?+?RPV LA is effective in the maintenance of HIV-1 virologic suppression in adults regardless of BMI category, with longer-length needles (?2 inches) recommend for those with BMI ?30?kg/m2 to accommodate individual body habitus and ensure appropriate administration. Active, not recruiting --> Completed

|||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Edurant (rilpivirine) / J&J
Review, Journal: Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine. (Pubmed Central) - Dec 18, 2023
Practical guidance on the clinical management of CAB+RPV LA dosing, including a detailed discussion using case-based scenarios that may be encountered in clinical practice, is provided. The clinician-administered CAB+RPV LA regimen has dosing management considerations that are flexible and considerate of the patient and has the potential to provide a highly desirable and efficacious alternative to daily oral antiretroviral therapy for many people with HIV-1.

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal: Predictors of post-switch viremia in people with HIV on injectable cabotegravir/rilpivirine. (Pubmed Central) - Dec 7, 2023
Despite virologic suppression at the time of switch and the perceived adherence benefits, participants still experienced blips or pLLV after switch to LAI CAB/RPV. Having detectable HIV RNA on oral therapy before switch was associated with detectable HIV RNA after switching.

|||||||||| Edurant (rilpivirine) / J&J, Rekambys (rilpivirine LA) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
PK/PD data, Journal: Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the vastus lateralis (lateral thigh) muscles of healthy adult participants. (Pubmed Central) - Dec 1, 2023
Cabotegravir and rilpivirine plasma pharmacokinetic profiles observed in this study support further evaluation of thigh administration in target populations of people living with HIV-1. Tolerability of cabotegravir + rilpivirine LA intramuscular lateral thigh injections was similar to gluteal administration.

||||||||||  Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Enrollment closed, Enrollment change, Trial primary completion date:  GLACIER: Study Using CABENUVA (clinicaltrials.gov) -  Nov 18, 2023
P4, N=44, Active, not recruiting,  Sponsor: ViiV Healthcare
Tolerability of cabotegravir + rilpivirine LA intramuscular lateral thigh injections was similar to gluteal administration. Recruiting --> Active, not recruiting | N=120 --> 44 | Trial primary completion date: Jul 2023 --> Feb 2024

|||||||||| Edurant (rilpivirine) / J&J, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Journal, Real-world evidence, Real-world: Cabotegravir (Pubmed Central) - Nov 15, 2023
Recruiting --> Active, not recruiting | N=120 --> 44 | Trial primary completion date: Jul 2023 --> Feb 2024 In this large US cohort, most monthly CAB

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Inclusion of women, Black and People of Colour (BPoC) and older adults in real-world and implementation studies evaluating long-acting injectable (LA-I) Cabotegravir (CAB) and Rilpivirine (RPV): a rapid review (ePosters area) - Oct 8, 2023 - Abstract #EACS2023EACS_1574;
Several studies failed to describe inclusion of important demographic groups in baseline demographic tables/text. We recommend future studies report on all characteristics and better represent both the population of people living with HIV locally and globally.

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Off-label use of long-acting injectable cabotegravir/rilpivirine in viremic patient living with HIV (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_1518;
Our case demonstrates the usefulness of CAB/RPV-LA in a patient not VS. The results add validity to the existing data on its use (1) and are optimistic so far with HIV-RNA <50 copies/mL However, our results are short-term, and follow-up studies are needed to clarify long-term outcomes.

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Off-label use of long-acting injectable cabotegravir/rilpivirine in viremic patient living with HIV (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_1517;
Our case demonstrates the usefulness of CAB/RPV-LA in a patient not VS. The results add validity to the existing data on its use (1) and are optimistic so far with HIV-RNA <50 copies/mL However, our results are short-term, and follow-up studies are needed to clarify long-term outcomes.

|||||||||| Descovy (emtricitabine/tenofovir alafenamide) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Single center study on participants living with HIV with isolated anticore antibody (anti-HBc) switching to long acting cabotegravir-rilpivirine therapy: Results from the SCohoLART study (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_1010;
Interestingly, one participant (PT9) had altered transaminases about 3 months after start of CAB/RPVLA, showing a seroreversion to HBsAg positivity, HBeAg appearance, with dramatically increased HBV-DNA, while anti-HCV and anti-HDV were negative; FTC/TAF was addded with a progressive decrease of HBV-DNA and normalization of transaminases. Conclusions :

|||||||||| Descovy (emtricitabine/tenofovir alafenamide) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Single center study on participants living with HIV with isolated anticore antibody (anti-HBc) switching to long acting cabotegravir-rilpivirine therapy: Results from the SCohoLART study (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_1009;
Interestingly, one participant (PT9) had altered transaminases about 3 months after start of CAB/RPVLA, showing a seroreversion to HBsAg positivity, HBeAg appearance, with dramatically increased HBV-DNA, while anti-HCV and anti-HDV were negative; FTC/TAF was addded with a progressive decrease of HBV-DNA and normalization of transaminases. Conclusions :

|||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Real life CABOTEGRAVIR (CAB) and RILPIVIRINE (RPV) pharmacokinetics among PLHIV treated with CAB RPV Long Acting (LA IM) (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_748;
Table 1 : M1 and M3 plasma CAB Cmin and RPV Cmin in real life setting. *results are expressed as median (IQR25%-75%) Conclusions :

|||||||||| Vocabria (cabotegravir oral) / ViiV Healthcare, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Real life CABOTEGRAVIR (CAB) and RILPIVIRINE (RPV) pharmacokinetics among PLHIV treated with CAB RPV Long Acting (LA IM) (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_747;
Table 1 : M1 and M3 plasma CAB Cmin and RPV Cmin in real life setting. *results are expressed as median (IQR25%-75%) Conclusions :

|||||||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
SOLAR 12-Month European Results: Randomized Switch Trial of CAB+RPV LA vs. Oral BIC/FTC/TAF (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_636;
P3
*results are expressed as median (IQR25%-75%) Conclusions : Mean adjusted HIVTSQs scores improved significantly (p<0.001) from baseline to M12 for LA (+3.64) vs. BIC/FTC/TAF participants (

|||||||||| Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) / Gilead, Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
SOLAR 12-Month European Results: Randomized Switch Trial of CAB+RPV LA vs. Oral BIC/FTC/TAF (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_635;
P3
Mean adjusted HIVTSQs scores improved significantly (p<0.001) from baseline to M12 for LA (+3.64) vs. BIC/FTC/TAF participants ( Mean adjusted HIVTSQs scores improved significantly (p<0.001) from baseline to M12 for LA (+3.64) vs. BIC/FTC/TAF participants (

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Efficacy, safety and implementation outcomes of Cabotegravir + Rilpivirine long-acting by country in the Cabotegravir And Rilpivirine Implementation Study in European Locations (CARISEL) (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_628;
High and comparable acceptability, appropriateness, and feasibility of CAB+RPV LA was seen across different countries. These data support CAB+RPV LA as a complete regimen for the maintenance of virologic suppression in PLWH in diverse European healthcare settings.

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Efficacy, safety and implementation outcomes of Cabotegravir + Rilpivirine long-acting by country in the Cabotegravir And Rilpivirine Implementation Study in European Locations (CARISEL) (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_627;
High and comparable acceptability, appropriateness, and feasibility of CAB+RPV LA was seen across different countries. These data support CAB+RPV LA as a complete regimen for the maintenance of virologic suppression in PLWH in diverse European healthcare settings.

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Cabotegravir + Rilpivirine long-acting efficacy and safety outcomes by sex at birth, age and race: a subgroup analysis of the CARISEL study (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_626;
P3
These data support CAB+RPV LA as a complete regimen for the maintenance of virologic suppression in PLWH in diverse European healthcare settings. Conclusions :

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Cabotegravir + Rilpivirine long-acting efficacy and safety outcomes by sex at birth, age and race: a subgroup analysis of the CARISEL study (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_625;
P3
Conclusions : Conclusions :

|||||||||| Rekambys (rilpivirine LA) / J&J
HIV viremias among patients who discontinued Cabotegravir(CAB)/ Rilpivirine(RPV) Long acting(LA) intramuscular(IM) in real-life setting (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_574;
Conclusions : Purpose :

|||||||||| Rekambys (rilpivirine LA) / J&J
HIV viremias among patients who discontinued Cabotegravir(CAB)/ Rilpivirine(RPV) Long acting(LA) intramuscular(IM) in real-life setting (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_573;
Purpose : Purpose :

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Safety of cabotegravir/rilpivirine long acting for individuals previously exposed to HBV infection (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_568;
Linear regression analysis failed to predict a significant FIB-4 evolution over time within the overall (b=-0.004, CI: -0.183-0.175, p=0.967), the HBV-exposed (b=-0.081, 95% CI: -0.440-0.279, p=0.659), and the unexposed population (b=-0.000, 95% CI: -0.180-0.180, p=0.997) (Figure 2). Conclusions :

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Safety of cabotegravir/rilpivirine long acting for individuals previously exposed to HBV infection (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_567;
Linear regression analysis failed to predict a significant FIB-4 evolution over time within the overall (b=-0.004, CI: -0.183-0.175, p=0.967), the HBV-exposed (b=-0.081, 95% CI: -0.440-0.279, p=0.659), and the unexposed population (b=-0.000, 95% CI: -0.180-0.180, p=0.997) (Figure 2). Conclusions :

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Marginalization related to material deprivation and ethnic concentration among patients receiving injectable ART at academic HIV clinics in Toronto (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_564;
Conclusions : Conclusions :

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
Marginalization related to material deprivation and ethnic concentration among patients receiving injectable ART at academic HIV clinics in Toronto (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_563;
Further efforts to ensure equitable access to CAB/RPV-LA are needed. Table 1: Demographics and HIV risk factors of included patients Figure 1: Distribution of included patients according to levels of marginalization

|||||||||| Rekambys (rilpivirine LA) / J&J
Total HIV-DNA trend in complex ART-experienced PLWH switching to CAB+RPV long-acting injectable: 28-week results in a home-care assistance setting (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_544;
Table 1: Demographics and HIV risk factors of included patients Figure 1: Distribution of included patients according to levels of marginalization Conclusions :

|||||||||| Rekambys (rilpivirine LA) / J&J
Total HIV-DNA trend in complex ART-experienced PLWH switching to CAB+RPV long-acting injectable: 28-week results in a home-care assistance setting (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_543;
Conclusions : Conclusions :

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
UK Multi-centre service evaluation of long-acting injectable CAB/RPV pathways (SHARE LAI-net) (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_538;
Conclusions : Purpose :

|||||||||| Cabenuva (cabotegravir long acting/rilpivirine long acting) / J&J, GSK, ViiV Healthcare, Pfizer, Shionogi
UK Multi-centre service evaluation of long-acting injectable CAB/RPV pathways (SHARE LAI-net) (ePosters) - Oct 8, 2023 - Abstract #EACS2023EACS_537;
Purpose : Purpose :



	Diseases Companies Products Productz Mechanisms of Action Sites